UBS AM’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

UBS AM’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-121,598	Closed	-$21M	–	2762
2015 Q1	$21M	Sell	121,598 -379,719	-76%	-$55.7M	0.02%	691
2014 Q4	$57.6M	Buy	501,317 +465,688	+1,307%	+$56.4M	0.05%	372
2014 Q3	$5.57M	Buy	35,629 +400	+1%	+$58K	0.01%	1012
2014 Q2	$4.34M	Buy	35,229 +300	+0.9%	+$33.2K	﹤0.01%	1066
2014 Q1	$3.62M	Sell	34,929 -511,679	-94%	-$52.4M	﹤0.01%	1121
2013 Q4	$49.2M	Sell	546,608 -67,881	-11%	-$5.41M	0.06%	357
2013 Q3	$41.1M	Sell	614,489 -150,106	-20%	-$10.3M	0.05%	379
2013 Q2	$50.6M	Buy	+764,595	New	+$43.7M	0.07%	312

Other funds holding SLXP

MMG

Monetary Management Group St Louis, Missouri $419M AUM 29.55% 1-Year Est. Return

UBS AM's SLXP Position: Q2 2015 in Review

UBS AM sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2015, closing a stake of 121,598 shares — an estimated $21M sold.

UBS AM first reported a position in SLXP in Q2 2013 and held it in 8 quarters. The position peaked at $57.6M in Q4 2014. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

UBS AM reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2015 after selling out during the quarter.
UBS AM sold 121,598 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2015, an estimated $21M.
UBS AM first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 8 quarters.
UBS AM's SALIX PHARMACEUTICALS LTD DEL position peaked at $57.6M in Q4 2014.
1 fund tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2015.

Based on UBS AM's 13F filing for Q2 2015, filed 12 Aug 2015.